Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RLD2106
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
01
Overview
RLD2106 is a drug code name that appeared in a completed clinical trial as part of a combination of investigational drugs evaluated for drug-drug interaction and safety in healthy volunteers. However, there is no publicly available information on its chemical nature, therapeutic class, mechanism of action, indication, or specific developer beyond its inclusion in this multiphase pharmacokinetic study. The trial assessing RLD2106 was sponsored by Hanmi Pharmaceutical Company. Further structural, pharmacological, or clinical details about RLD2106 are not available in any referenced scientific or regulatory data sources.
- Other names
- RLD2106RLD-2106RLD 2106
Beyond the preview
Go deeper on RLD2106.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RLD2106.